BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The global ophthalmic drug market is forecast to surpass $60 b
 illion USD by 2025 with increasing focus from the industry on alternative
  delivery approaches and improving the effectiveness of the current reper
 toire of drugs in order to grow away from intravitreal injections and oth
 er surgical approaches to ocular therapy. With 50% of the global populati
 on predicted to have complications in their sight within the next few dec
 ades\, ophthalmic medicine is set to become one of the biggest industries
  in pharmaceuticals.\n\nAs Europe's leading Ophthalmic Drugs conference\,
  we will explore new discoveries in the treatment of ocular disease\, inn
 ovations in combination technologies\, and the utterly unique challenges 
 that are faced in the treatment of one of the most complex organs in the 
 body.\n\nThis two-day agenda will offer peer-to-peer networking opportuni
 ties with leaders in the ophthalmic sphere\, from Heads of Drug Developme
 nt and Senior Directors of Ophthalmology\, all the way to academic foreru
 nners in the research into ocular therapy.To register or for more informa
 tion visit: www.ophthalmicdrugs.com/evvntwl\n\nBENEFITS OF ATTENDING:- GA
 IN insight into the latest treatments for Glaucoma and Dry-Eye Disease fr
 om Aerie Pharmaceuticals- EXAMINE the challenges of designing the right d
 rug for topical drug delivery to the retina with Ocuterra Therapeutics- U
 NDERSTAND the advancements in treatments for inherited retinal diseases f
 rom ProQR- EXPLORE the design and characteristics of a durable local ocul
 ar formulation with forwardvue pharma- DISCUSS patient centricity as a dr
 iver for drug delivery innovation in ophthalmology with Roche- DISCOVER a
  novel target for Geographic Atrophy and Diabetic Retinopathy with Inflam
 mX Therapeutics- REVIEW the hidden and unmet clinical need of Diabetic Ma
 cular Ischemia with Boehringer Ingelheim- RECEIVE key updates on ocular g
 ene therapy from SparingVision- UNCOVER the clinical development and regu
 latory landscape for ophthalmic products in the UK and Europe from Bayer\
 n\nPLUS\, TWO INTERACTIVE POST CONFERENCE WORKSHOPSWednesday 24th Novembe
 r 2021\n\nA: Novel Platforms in Ocular Drug DeliveryWorkshop Leaders:Dr. 
 Thakur Raghu Raj Singh\, Reader in Pharmaceutics\, Queen's university Bel
 fast andLaurence Fitzhenry\, Lecturer\; Project Coordinator\, ORBITAL-ITN
 \n\nB: Ophthalmic Drug Delivery Development - Trials and TribulationsWork
 shop Leaders:Brian Levy\, CEO\, InflammX Therapeutics\n\nWHO SHOULD ATTEN
 D:&nbsp\;- CEOs\, CMOs and Researchers from pharmaceutical companies invo
 lved in ocular drug development\, in addition to biotechnologies involved
  in ocular drug delivery research.- Heads and VPs of Retinal Health\, Ocu
 lar Therapy\, Medical Safety\, and Ophthalmology.- Professors\, Senior Le
 cturers\, and Specialists in Ocular biology and immunology\, and clinical
  pharmaceuticals\n\nEarly-Bird Rates- BOOK BY 30TH JUNE TO SAVE £200- BOO
 K BY 30TH SEPTEMBER TO SAVE £100\n\nSOCIAL MEDIA HANDLESTwitter: @SMiPhar
 m #OphthalmicDrugsLinkedIn: follow our company page - search 'SMi Pharma'
 \n\nAdditional Contact Info:T: +44 (0)20 7827 6088E: hsidhu@smi-online.co
 .uk\n
DTEND:20211123T173000
DTSTAMP:20260512T232945Z
DTSTART:20211122T090000
LOCATION:TBC\, London\, \,
SEQUENCE:0
SUMMARY:The global ophthalmic drug market is forecast to surpass $60 billi
 on USD by 2025 with increasing focus from the industry on alternative del
 ivery ap...
UID:44cbfdcb-26c2-4750-bb66-639cbb1e60c1
END:VEVENT
END:VCALENDAR